DrugPatentWatch Database Preview

Details for Patent: 8,039,479

Which drugs does patent 8,039,479 protect, and when does it expire?

Patent 8,039,479 protects ZYKADIA and is included in one NDA.

This patent has ninety-one patent family members in forty-four countries.

Summary for Patent: 8,039,479

Title:	Compounds and compositions as protein kinase inhibitors
Abstract:	The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
Inventor(s):	Michellys; Pierre-Yves (San Marcos, CA), Pei; Wei (San Diego, CA), Marsilje; Thomas H. (San Diego, CA), Chen; Bei (San Diego, CA), Uno; Tetsuo (San Diego, CA)
Assignee:	IRM LLC (Hamilton, BM)
Application Number:	11/943,436
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 8,039,479

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Novartis Pharms Corp	ZYKADIA	ceritinib	CAPSULE;ORAL	205755-001	Apr 29, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up	Y	Y			➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,039,479

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,399,450	Compounds and compositions as protein kinase inhibitors	➤ Sign Up
8,372,858	Compounds and compositions as protein kinase inhibitors	➤ Sign Up
8,957,081	Compounds and compositions as protein kinase inhibitors	➤ Sign Up
8,440,681	2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,039,479

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Tunisia	2009000225	➤ Sign Up
El Salvador	2009003290	➤ Sign Up
San Marino	P200900058	➤ Sign Up
San Marino	AP200900058	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,039,479

For more information try a trial or see the plans and pricing